Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

MLA

McGovern, Rachel A., et al. “Maraviroc Treatment in Non-R5-HIV-1-Infected Patients Results in the Selection of Extreme CXCR4-Using Variants with Limited Effect on the Total Viral Setpoint.” The Journal of Antimicrobial Chemotherapy, vol. 68, no. 9, Sept. 2013, pp. 2007–14. EBSCOhost, https://doi.org/10.1093/jac/dkt153.

APA

McGovern, R. A., Symons, J., Poon, A. F. Y., Harrigan, P. R., van Lelyveld, S. F. L., Hoepelman, A. I. M., van Ham, P. M., Dong, W., Wensing, A. M. J., & Nijhuis, M. (2013). Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint. The Journal of Antimicrobial Chemotherapy, 68(9), 2007–2014. https://doi.org/10.1093/jac/dkt153

Chicago

McGovern, Rachel A, Jori Symons, Art F Y Poon, P Richard Harrigan, Steven F L van Lelyveld, Andy I M Hoepelman, Petra M van Ham, Winnie Dong, Annemarie M J Wensing, and Monique Nijhuis. 2013. “Maraviroc Treatment in Non-R5-HIV-1-Infected Patients Results in the Selection of Extreme CXCR4-Using Variants with Limited Effect on the Total Viral Setpoint.” The Journal of Antimicrobial Chemotherapy 68 (9): 2007–14. doi:10.1093/jac/dkt153.